Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Telithromycin in Respiratory Tract Infections
- Conditions
- Respiratory Tract Infections
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00261105
GEMOX: Oxaliplatin in Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT00261092
- Locations
- 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of
American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
- Conditions
- Atrial FlutterAtrial Fibrillation
- Interventions
- Drug: placebo
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 629
- Registration Number
- NCT00259376
- Locations
- 🇦🇺
sanofi-aventis Australia administrative office, Macquarie Park, Australia
🇿🇦Sanofi-Aventis Administrative Office, Midrand, South Africa
Immunogenicity and Safety of Pentaxim™ in an Indian Population
- Conditions
- DiphtheriaTetanusPolioPertussisHaemophilus Infections
- Interventions
- Biological: Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 226
- Registration Number
- NCT00259337
EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)
- Conditions
- Atrial FibrillationAtrial Flutter
- Interventions
- Drug: placebo
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 615
- Registration Number
- NCT00259428
- Locations
- 🇭🇺
Sanofi- Aventis Administrative Office, Budapest, Hungary
🇬🇧Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Oxaliplatin in Rectal Cancer
- Conditions
- Rectal Neoplasms
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 46
- Registration Number
- NCT00259363
- Locations
- 🇪🇸
Sanofi-Aventis, Barcelona, Spain
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
- Conditions
- Esophageal Neoplasms
- Interventions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT00259402
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
- Conditions
- SmallpoxPoxvirus Infection
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 230
- Registration Number
- NCT00258947
Insulin Glargine During and After the Period of Fasting in Ramadan
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 450
- Registration Number
- NCT00258804
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Lung Neoplasms
- Interventions
- Other: Docetaxel + gemcitabine + carboplatin + radiotherapy
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT00258739
- Locations
- 🇪🇸
Sanofi-Aventis, Barcelona, Spain